Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
98
Frequently Asked Questions
What is Market Cap of Scribe Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Scribe Therapeutics Inc. market cap is $350.34M.
What is the 52-week high for Scribe Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Scribe Therapeutics Inc. 52 week high is $25.49 as of July 25, 2026.
What is the 52-week low for Scribe Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Scribe Therapeutics Inc. 52 week low is $15.00 as of July 25, 2026.
What is Scribe Therapeutics Inc. stock price today?
Scribe Therapeutics Inc. stock price today is $21.65.
What was Scribe Therapeutics Inc. stock price yesterday?
Scribe Therapeutics Inc. stock price yesterday was $15.00.
What is the Price-to-Book ratio of Scribe Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Scribe Therapeutics Inc. P/B ratio is -2.207.
What is the 50-day moving average of Scribe Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Scribe Therapeutics Inc. 50-day moving average is $18.33.
How many employees does Scribe Therapeutics Inc. have?